|
|
News Breaks
|
January 10, 2012
|
| 08:04 EDT |  | CBST |
| theflyonthewall.com: | Cubist, Hydra announce plans to begin phase 1 trial for Novel TRPA1 | | Cubist Pharmaceuticals and Hydra Biosciences announced plans to begin a Phase 1 clinical trial for a small molecule antagonist of the human Transient Receptor Potential Ankyrin repeat 1 ion channel discovered in a collaboration between Cubist and Hydra. This Phase 1 trial is the first step in a clinical development program designed to evaluate the potential of this TRPA1 investigational product to treat acute pain and certain inflammatory conditions. Under the collaboration, the companies recently identified and completed preclinical testing on a potent, selective TRPA1 antagonist, CB-625, and filed for regulatory approval to initiate human clinical studies. The open-label, dose-escalation study to assess the safety and pharmacokinetics of CB-625 in healthy volunteers will be conducted in the Netherlands and is expected to start in Q1. :theflyonthewall.com |
|
|
News For CBST From The Last 14 Days Check below for free stories on CBST the last two weeks.
There is 1 item on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
May 14, 2012
|
| 16:02 EDT | | CBST |
| theflyonthewall.com: | Cubist announces presentations of data from phase 2 studies of CB-5945 | | Cubist Pharmaceuticals announced that the results from the Phase 2 studies of CB-5945 in patients with chronic non-cancer pain and opioid-induced constipation will be presented at the 31st Annual Scientific Meeting of the American Pain Society taking place May 16 to 19, 2012, in Honolulu and during Digestive Disease Week 2012 taking place May 19 to 22, 2012, in San Diego. Studies 242 and 243 each met the primary endpoint of change from baseline in the number of spontaneous bowel movements over a four-week treatment period. :theflyonthewall.com |
|
|
|
|
|
